KBY Biotech Indexv0.0.34
Search
← Pipeline|Zanuratamab

Zanuratamab

Phase 1
NIC-6449
By Nichi-Iko
Source: Trial-derived·Trials: 1
Modality
Vaccine
MOA
CAR-T BCMA
Target
TIM-3
Pathway
Apoptosis
TTR AmyloidosisFSGS
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
Jul 2021
→ Jun 2030
Phase 1Current
NCT06687150
1,019 pts·TTR Amyloidosis
2021-07→2030-06·Completed
1,019 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-254.2y awayInterim· TTR Amyloidosis
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1
Complet…
Catalysts
Interim
2030-06-25 · 4.2y away
TTR Amyloidosis
Completed|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT06687150Phase 1TTR AmyloidosisCompleted1019Mayo
Competitors (10)
DrugCompanyPhaseTargetMOA
VoxacilimabPfizerPhase 2TYK2CAR-T BCMA
NVO-9087Novo NordiskPhase 1/2TauCAR-T BCMA
FixazanubrutinibAmgenPhase 2PI3KαCAR-T BCMA
REG-6699RegeneronPhase 2/3TIM-3FcRni
REG-8074RegeneronPhase 2/3KRASG12CCAR-T BCMA
NidasacituzumabUnited TherapeuticsPhase 1/2TIM-3ALKi
JAZ-8729Jazz PharmaPhase 2/3FcRnCAR-T BCMA
LiratinibKrystal BiotechNDA/BLATIM-3EZH2i
DoxazasiranAxsomePhase 1TIM-3IL-17i
ACA-2691Acadia PharmaPhase 3BCMACAR-T BCMA